{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-23-000457","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.622330+00:00","generated_at":"2026-06-09T10:39:42.039147+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioVie presents blinded Phase 3 NE3107 data at CTAD; cognitive, biomarker improvements observed","bullets":["Blinded data (n=322) show statistically significant population changes from baseline on ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, ADL.","Apparent reduction in amyloid burden: 36.5% of PrecivityAD-positive patients reverted to negative after 30 weeks.","Significant increases in insulin and beta cell function (HOMA2-%B +13.5%, p<0.0001) without hypoglycemia.","FDG-PET SUVRs increased in 10 of 21 sub-study patients, suggesting reduced amyloid burden.","Company expects unblinded topline data in late November or early December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-23-000457","json":"https://secwatch.observer/filing/0001520138-23-000457.json","markdown":"https://secwatch.observer/filing/0001520138-23-000457.md","text":"https://secwatch.observer/filing/0001520138-23-000457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013823000457/0001520138-23-000457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013823000457/bivi-20231025_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T10:39:42.039147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}